New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation
GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the publication of a comprehensive review article, "Brincidofovir in the Era of Mpox," in the peer-reviewed journal Expert Review of Anti-infective Therapy.1 This publication includes an overview of brincidofovir, in vitro and in vivo data, including human case studies of the investigational use of brincidofovir, the current evaluation for treating mpox infections in adults and pediatrics in the Democratic Republic of Congo, and the potential for combination therapy with tecovirimat for immunocompromised patients with severe disease.
“We believe in the importance of assessing brincidofovir, an antiviral, for this public health threat and we look forward to advancing our research across mpox as it’s a global disease of increasing concern,” said Simon Lowry, M.D., chief medical officer and head of research and development at Emergent.
Mpox, formerly known as monkeypox, continues to pose a significant public health challenge, with ongoing regional and global outbreaks particularly in Central and West Africa. On August 14, 2024, the World Health Organization (WHO) declared the current mpox outbreak a global Public Health Emergency of International Concern (PHEIC).2 This marks the second mpox PHEIC declared by the WHO in the past two years, which followed the regional emergency declaration by the Africa Centres for Disease Control and Prevention (Africa CDC) on August 13, 2024.3 This month, the U.S. Centers for Disease Control and Prevention issued an updated report on the surge of mpox around the world.4
As part of the ongoing effort to identify safe and effective treatments for mpox, brincidofovir is currently being evaluated by the Africa CDC in partnership with PANTHER (PANdemic preparedness plaTform for Health and Emerging infectious Response) in the , a double-blind, placebo-controlled clinical trial for people diagnosed with mpox, which initiated in January 2025. The study has received initial funding from Horizon Europe and Africa CDC.
Dr. Lowry continued, “In addition to our engagement with PANTHER on the MOSA trial, this scientific review provides insights into the investigational use of brincidofovir in the treatment of mpox, and we are pleased this publication is available for the broader medical community.”
Please see full for TEMBEXA® (brincidofovir) for additional safety information.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our and follow us on , , , and .
Safe Harbor Statement
We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate.
Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances.
Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
Media Contact:
Assal Hellmer
Vice President, Communications
__________________________
1
2
3
4
